Explore our portfolio of clinical trials dedicated to endometrial cancer research. These trials focus on advancing diagnostic techniques, evaluating novel therapies, and improving patient management to achieve better outcomes.
This resource is intended for patients, healthcare professionals, and researchers seeking up-to-date information on ongoing and completed studies within the NSGO-CTU network.
For detailed eligibility criteria, site information, or additional inquiries, please contact the assigned Project Manager.
ENGOT-EN1-NSGO/FANDANGO
A randomized phase II trial of first-line combination chemotherapy with Nintedanib/placebo for patients with advanced or recurrent endometrial cancer.
ENGOT-EN2-DGCG
A phase II Trial of postoperative chemotherapy or no further treatment for patietns with node-negative stage I-II intermediate or high risk endometrial cancer.
ENGOT-EN3-NSGO/PALEO
A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer.
ENGOT-EN6/NSGO-CTU/RUBY I
A Phase 3 Randomized Open-Label Study of TSR-042, an anti-PD-1 Mono-clonal Antibody vs. Investigator’s Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer
ENGOT-EN6/NSGO-CTU/RUBY II
A Phase 3 Randomized Open-Label Study of TSR-042, an anti-PD-1 Mono-clonal Antibody vs. Investigator’s Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer
ENGOT-EN10/DUO-E
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E).
ENGOT-EN11/BGOG/KEYNOTE-B21
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
ENGOT-EN15/MITO
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15).
ENGOT-EN23/GOG-3095/MK-2870-005
Phase 3, randomized, active-controlled, open-label, multicenter study to compare the efficacy and safety of MK-2870 monotherapy versus treament of physician’s choise in participants with endometrial cancer who have received prior platinum-based chemotherapy and immunotherapy.
ENGOT-EN24/DESTINY-Endometrial01
A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer.
ENGOT-EN25/BNT323-01
A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer.